Overview

Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease

Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
An 18-month randomized, double-blind, placebo-controlled study to compare the effect of fixed dose ferric citrate versus placebo in patients with advanced chronic kidney disease (eGFR ≤20 ml/min/1.73m2) on the composite endpoint of time to initiation of maintenance dialysis or all-cause mortality.
Phase:
Phase 3
Details
Lead Sponsor:
USRC Kidney Research
Collaborator:
Akebia Therapeutics